Welcome to FlavorDB

Content

Generals
Classification
Quality
Toxicity & Safety
Receptors

Compound Summary

General Compound Information

Erythromycin

Description

Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It derives from an erythronolide A. It is a conjugate base of an erythromycin A(1+).

Synonyms

erythromycin; 114-07-8; Erythromycin A; E-Mycin; Ilotycin;

Abomacetin;Erymax;Erythromycinum;Emgel;Erycette;Robimycin;Erythro-Statin;E-Glades;Erythrocin;Ery-Tab;E-Base;Eritromicina;Erythromycine;Erygel;Sansac;Erythra-Derm;Akne-Mycin;ERYC;Erythromycin base;T-Stat;Eryacne;R-P Mycin;E-Solve 2;Torlamicina;Eryderm;C-Solve-2;Pantomicina;A/T/S;erythro;Erythroguent;Eritrocina;Propiocine;Stiemycin;Ermycin;Erycen;Aknin;Theramycin Z;erythromycin-A;Ak-Mycin;Erythromast 36;Benzamycin;Emycin;Erytab;Inderm;Retcin;(-)-ERYTHROMYCIN;CHEMBL532;Dumotrycin;Mephamycin;DTXSID4022991;CHEBI:42355;Wemid;J01FA01;Eryc Sprinkles;MFCD00084654;NSC-55929;63937KV33D;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione;Erythromycin C-13;Endoeritrin;Eritomicina;Erythroderm;Erytrociclin;Pharyngocin;Proterytrin;Acneryne;Acnesol;Aknemycin;Derimer;Deripil;Erisone;Eryacnen;Erydermer;Eryhexal;Erysafe;Iloticina;Latotryd;Lederpax;Mercina;Oftamolets;Pantoderm;Pantodrin;Primacine;Romycin;Stiemicyn;Tiprocin;Emuvin;Erecin;Erymed;Erytop;NCI-C55674;AustriaS;Eros;Ery-maxin;Erythro-Teva;Sans-acne;Erimycin-T;Ery-Diolan;Inderm Gel;Del-Mycin;Aknederm Ery Gel;Udima Ery Gel;Eryc 125;Emu-Ve;8HPH7ND0LN;Skid Gel E;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione;Akne Cordes Losung;ERY;Ilosone (estolate);Ilotycin T.S.;E-Mycin (base);Ery-Tab (base);Emu-V;Ery-B;E-Base (base);DTXCID102991;ERYC (base);N-Methylerythromycin A;PCE Dispertab (base);Eryc-125;Eryc-250;Eritromicina [INN-Spanish];Erythromycine [INN-French];Erythromycinum [INN-Latin];Erythromycin, labeled with carbon-13;Oftalmolosa Cusi Eritromicina;Staticin (TN);Akne-mycin (TN);Erygel (TN);Eryc (TN);T-stat (TN);Pce (TN);SR-05000001618;Sentry AQ mardel maracyn;9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;erthromycin;Erythromycines;NSC55929;CCRIS 9078;UNII-63937KV33D;HSDB 3074;NCGC00094670-01;Erythromycin [USP:INN:BAN:JAN];(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione;CAS-114-07-8;Prestwick_205;EINECS 204-040-1;NSC 55929;215031-94-0;82343-12-2;Spectrum_000115;Spectrum_000659;AI3-50138;EM-A;Prestwick3_000151;Spectrum2_000759;Spectrum2_001263;Spectrum4_000538;Spectrum5_001596;UNII-8HPH7ND0LN;ERYTHROMYCIN [MI];E0751;ERYTHROMYCIN [INN];ERYTHROMYCIN [JAN];PCE (ERYTHROMYCIN);EC 204-040-1;ERYTHROMYCIN [HSDB];SCHEMBL2601;ERYTHROMYCIN [VANDF];BSPBio_000282;BSPBio_002480;ERYTHROMYCIN [MART.];KBioGR_001175;KBioSS_000555;KBioSS_001139;MLS001066618;BIDD:GT0017;DivK1c_000294;DivK1c_000397;DivK1c_000702;ERYTHROMYCIN [USP-RS];ERYTHROMYCIN [WHO-DD];ERYTHROMYCIN [WHO-IP];SPECTRUM1500280;SPBio_000778;SPBio_001226;BPBio1_000312;GTPL1456;Erythromycin (JP17/USP/INN);HMS500O16;KBio1_000294;KBio1_000397;KBio1_000702;KBio2_000555;KBio2_001139;KBio2_003123;KBio2_003707;KBio2_005691;KBio2_006275;ERYTHROMYCIN [GREEN BOOK];NINDS_000294;NINDS_000397;NINDS_000702;ERYTHROMYCIN [ORANGE BOOK];HMS1920M04;HMS2091D05;HMS2095O04;HMS3712O04;Pharmakon1600-01500280;ERYTHROMYCIN [EP MONOGRAPH];ACT03320;HY-B0220;RKL10096;ERYTHROMYCIN [USP MONOGRAPH];Tox21_111311;Tox21_111869;Tox21_300515;BDBM50344942;CCG-38992;LMPK04000006;NSC756759;ZINC85534336;ERYTHROMYCINUM [WHO-IP LATIN];AKOS015895249;DB00199;NSC-756759;BENZAMYCIN COMPONENT ERYTHROMYCIN;IDI1_000294;IDI1_000397;IDI1_000702;SMP1_000119;NCGC00179619-01;NCGC00179619-02;NCGC00179619-03;NCGC00254234-01;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;AC-12744;AC-12901;SMR000544946;ERYTHROMYCIN COMPONENT OF BENZAMYCIN;Erythromycin, potency: >=850 mug per mg;Erythromycin, tested according to Ph.Eur.;SBI-0051368.P003;Erythromycin, N-demethyl-N-(methyl-11C)-;Erythromycin 1000 microg/mL in Acetonitrile;Erythromycin, meets USP testing specifications;C01912;D00140;E-3250;Erythromycin, plant cell culture tested, ~98%;AB00051981_09;AB00051981_10;Erythromycin, Biotechnology Performance Certified;Erythromycin estolate impurity, free erythromycin-;Q213511;SR-01000799155;Erythromycin, Antibiotic for Culture Media Use Only;Erythromycin, BioReagent, suitable for cell culture;SR-01000799155-2;SR-05000001618-1;SR-05000001618-2;BRD-K63550407-001-13-5;BRD-K63550407-028-03-9;Z2587996953;Erythromycin A, British Pharmacopoeia (BP) Reference Standard;Erythromycin A, European Pharmacopoeia (EP) Reference Standard;Erythromycin, United States Pharmacopeia (USP) Reference Standard;ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN [EP IMPURITY];ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN- [USP IMPURITY];Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard;Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione;[3R-(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione;

FlavorDB ID

73

PUBCHEM ID

12560

Molecular Weight

733.9

Molecular Formula

C37H67NO13

Openeye Can Smiles

CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O

IUPAC Inchikey

ULGZDMOVFRHVEP-RWJQBGPGSA-N

Network

Shown in network

Similarity

Show/Hide similarity panel

Compound Classification

Classification (Parent Nodes)

ClassyFire Ontology

Compound Quality

Quality information of this compound is not available!

Compound Toxicity and Food Additive Safety (OFAS)

Toxicity Summary
Link to the Distributed Structure-Searchable Toxicity (DSSTox) Database
LD50 The oral LD50 of erythromycin in rats is 9272 mg/kg.[L7279] Overdose information Symptoms of overdose may include diarrhea, nausea, stomach cramps, and vomiting. Erythromycin should immediately be discontinued in cases of overdose. Rapid elimination of unabsorbed drug should be attempted. Supportive measures should be initiated. Erythromycin is not adequately removed by peritoneal dialysis or hemodialysis.[L7261]
Source: DrugBank or Hazardous Substances Data Bank (HSDB)

Receptors

Receptor	REFERENCE	EC50 [µM]	Effective Concentration [µM]
TAS2R7	details	Activated	Activated
TAS2R10	details	Activated	300.00

Consensus Spectra

Spectrum Type	Spectrum View	Description	Polarity
Experimental LCMS	view	LCMS_Positive	positive
Experimental LCMS	view	LCMS_Negative	negative